Affymax Biopharm Dissolves After Fatal Drug Reactions

Source: Market Watch

Jun 25, 2014

Affymax Inc., a Cupertino, California-based biopharmaceutical company, has announced that its Board of Directors has approved the liquidation and dissolution of the company -- two weeks after dissolving its agreement with partner company Takeda surrounding serious issues with jointly-licensed drug, Omontys.

In February 2013, Affymax and Takeda voluntarily recalled all lots of Omontys anemia drug and suspended promotional activities in the U.S. following postmarketing reports of serious hypersensitivity reactions including anaphylaxis. Takeda's detailed investigation has confirmed no quality or manufacturing issues were present but has not identified a specific root cause for the reactions.

The liquidation and dissolution of Affymax is subject to stockholder approval, and the company plans to distribute all available cash to its stockholders as soon as legally permitted.

Read the Market Watch press release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments